A detailed history of Price T Rowe Associates Inc transactions in Legend Biotech Corp stock. As of the latest transaction made, Price T Rowe Associates Inc holds 10,949,120 shares of LEGN stock, worth $477 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
10,949,120
Previous 10,808,216 1.3%
Holding current value
$477 Million
Previous $650 Million 5.57%
% of portfolio
0.08%
Previous 0.09%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$55.06 - $69.99 $7.76 Million - $9.86 Million
140,904 Added 1.3%
10,949,120 $614 Million
Q4 2023

Feb 14, 2024

BUY
$57.25 - $69.74 $63.8 Million - $77.7 Million
1,114,848 Added 11.5%
10,808,216 $650 Million
Q3 2023

Nov 14, 2023

BUY
$63.16 - $76.5 $41.8 Million - $50.6 Million
662,044 Added 7.33%
9,693,368 $651 Million
Q2 2023

Aug 14, 2023

BUY
$46.28 - $75.01 $367 Million - $596 Million
7,939,175 Added 726.93%
9,031,324 $623 Million
Q1 2023

May 15, 2023

BUY
$43.42 - $57.37 $19 Million - $25.1 Million
437,630 Added 66.86%
1,092,149 $52.7 Million
Q4 2022

Feb 14, 2023

SELL
$38.8 - $55.46 $49,625 - $70,933
-1,279 Reduced 0.2%
654,519 $32.7 Million
Q3 2022

Nov 14, 2022

BUY
$38.15 - $57.1 $3.38 Million - $5.06 Million
88,643 Added 15.63%
655,798 $26.8 Million
Q2 2022

Aug 15, 2022

BUY
$33.54 - $55.0 $19 Million - $31.2 Million
567,155 New
567,155 $31.2 Million
Q2 2021

Aug 16, 2021

SELL
$25.8 - $41.09 $3.21 Million - $5.1 Million
-124,229 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$23.55 - $32.4 $10.7 Million - $14.8 Million
-455,548 Reduced 78.57%
124,229 $3.61 Million
Q4 2020

Feb 16, 2021

BUY
$25.8 - $32.39 $15 Million - $18.8 Million
579,777 New
579,777 $16.3 Million

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $7.29B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.